Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
about
Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in CambodiaHigh prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsHigh prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility
P2860
Q28535850-43F6F2F1-0870-423E-A73B-46A0A1459080Q28543358-BEC9BD24-4121-4112-BC9D-E0AFD494E8C5Q33603586-87D18384-84E9-4B4A-88BF-C24971756D19Q33743954-AD09596B-7858-481B-ADF1-53DBC8857943Q33900459-59C691EC-D24B-4DA6-8CC4-0F511295C619Q34414078-7A41EE3C-F3D0-4B7C-B35C-24D777016E3AQ34647936-D23D1E0C-DF70-488E-BE86-62EB8A5EF030Q35215399-F924BF90-0DFC-4E98-A632-9DDD7135FAF5Q38262356-1119B029-429F-49C9-A3C4-B16ECE03DFD0Q39142877-078D4540-C118-4665-8C3B-652E902C3FE2Q39360243-3E0BF3E1-8AF8-4EDF-B0A1-C5F1CF2FCF97Q40432241-03C32928-5150-4650-8F74-468960429201Q40902737-D86E987B-6087-4A82-8E86-455BE3A6EDAEQ41428068-9BEB3A3A-A709-4E2F-B895-13F4C0D72A6CQ41820283-D0183A96-3086-40DD-9CFA-AF3E059FBC23Q42151695-2345304D-E3F0-4C86-846A-4D2AA6B40973
P2860
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Human immunodeficiency virus t ...... d with abacavir or lamivudine.
@en
type
label
Human immunodeficiency virus t ...... d with abacavir or lamivudine.
@en
prefLabel
Human immunodeficiency virus t ...... d with abacavir or lamivudine.
@en
P2093
P2860
P1476
Human immunodeficiency virus t ...... d with abacavir or lamivudine.
@en
P2093
Charles Craig
Chris Stone
Margaret Tisdale
Mounir Ait-Khaled
Philip Griffin
P2860
P304
P356
10.1128/AAC.48.4.1413-1415.2004
P407
P577
2004-04-01T00:00:00Z